Expert consensus on the clinical application of Qiliqiangxin for chronic heart failure
-
摘要: 芪苈强心作为中医脉络学说指导研发的创新中药，近20年来治疗心力衰竭(心衰)药理作用机制和改善心血管结局方面的证据日益增加，显著降低心血管终点事件。但芪苈强心治疗慢性心衰的药理作用机制尚不被临床医生熟知。为进一步规范和指导芪苈强心在心衰治疗中的合理应用，本专家共识对芪苈强心治疗慢性心衰的组方特点和药理作用机制进行了归纳，对临床应用给予推荐。Abstract: Qiliqiangxin(QLQX), as an innovative traditional Chinese medicine developed under the guidance of Luobing theory, has seen increasing evidence over the past 20 years supporting its pharmacological mechanisms in treating heart failure and improving cardiovascular outcomes, significantly reducing cardiovascular endpoint events. However, the pharmacological mechanisms of QLQX in the treatment of chronic heart failure(CHF) are not yet well known among clinicians. This expert consensus aims to further standardize and guide the rational use of QLQX in patients with heart failure, summarizing the compositional characteristics and pharmacological mechanisms of QLQX for treating CHF, and providing recommendations for its clinical application.
-
Key words:
- chronic heart failure /
- Qiliqiangxin /
- randomized clinical trials /
- mechanism /
- cardiovascular outcome
-
-
图 1 芪苈强心“气血水同治分消”组方特点
Figure 1. The characteristics of QLQX formula for treating qi, blood, and water aspect
图 2 芪苈强心治疗慢性心衰的作用机制示意图
Figure 2. Schematic diagram of pharmacological mechanism of Qiliqiangxin in treating chronic heart failure
表 1 推荐级别的定义
Table 1. Definition of recommendation levels
级别 含义 Ⅰ类 已证实和(或)一致公认有益、有用和有效的操作或治疗 Ⅱa类 有关证据/观点倾向于有用和(或)有效，应用这些操作或治疗是合理的 Ⅱb类 有关证据/观点尚不能被充分证明有用和(或)有效，可考虑应用 Ⅲ类 已证实和(或)一致公认无用和(或)无效，并对一些病例可能有害的操作或治疗，不推荐使用 
下载: 导出CSV
表 2 证据级别的定义
Table 2. Definition of evidence levels
级别 含义 A 资料来源于多项随机对照临床试验或荟萃分析 B 资料来源于单项随机对照临床试验或多项非随机对照研究 C 仅为专家共识意见和(或)小型临床试验、回顾性研究或注册登记研究
下载: 导出CSV
-
[1] 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275.
[2] Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials[J]. Lancet, 2020, 396(10244): 121-128. doi: 10.1016/S0140-6736(20)30748-0
[3] Packer M. Qiliqiangxin: a multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms?[J]. Eur J Heart Fail, 2023, 25(12): 2130-2143. doi: 10.1002/ejhf.3068
[4] Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group[J]. N Engl J Med, 1991, 325(21): 1468-1475. doi: 10.1056/NEJM199111213252103
[5] Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope[J]. J Am Coll Cardiol, 1988, 12(5): 1299-1317. doi: 10.1016/0735-1097(88)92615-0
[6] Movsesian MA. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate[J]. J Am Coll Cardiol, 1999, 34(2): 318-324. doi: 10.1016/S0735-1097(99)00220-X
[7] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology(ESC)developed with the special contribution of the heart failure association(HFA)of the ESC[J]. Eur Heart J, 2016, 37(27): 2129-2200. doi: 10.1093/eurheartj/ehw128
[8] Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-reduced trial[J]. Eur J Heart Fail, 2019, 21(10): 1270-1278. doi: 10.1002/ejhf.1536
[9] Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383(15): 1413-1424. doi: 10.1056/NEJMoa2022190
[10] McMurray JJV, Docherty KF, de Boer RA, et al. Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials[J]. Circulation, 2024, 149(11): 825-838. doi: 10.1161/CIRCULATIONAHA.123.065061
[11] Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction[J]. JACC Heart Fail, 2022, 10(2): 73-84. doi: 10.1016/j.jchf.2021.09.004
[12] 国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组. 2020中国心力衰竭医疗质量控制报告[J]. 中国循环杂志, 2021, 36(3): 221-238.
[13] 常丽萍. 吴以岭院士领导团队创新获国家科技进步一等奖[J]. 天津中医药, 2020, 37(2): 240.
[14] 吴以岭. 脉络学说构建及其指导血管病变防治研究[J]. 中国中西医结合杂志, 2017, 37(2): 147-148.
[15] 吴以岭. 脉络学说构建及其指导血管病变防治药物的研究[J]. 实用心电学杂志, 2018, 27(4): 229-233.
[16] Wang T, Hou B, Qin H, et al. Qili Qiangxin(QLQX)capsule as a multi-functional traditional Chinese medicine in treating chronic heart failure(CHF): A review of ingredients, molecular, cellular, and pharmacological mechanisms[J]. Heliyon, 2023, 9(11): e21950. doi: 10.1016/j.heliyon.2023.e21950
[17] 常丽萍. 芪苈强心胶囊治疗慢性心力衰竭的作用机理及代谢组学研究[D]. 石家庄: 河北医科大学, 2017.
[18] Fu JZ, Chang LP, Harms AC, et al. A metabolomics study of qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach[J]. Sci Rep, 2018, 8(1): 3688. doi: 10.1038/s41598-018-22074-6
[19] Yun WJ, Yao ZH, Fan CL, et al. Systematic screening and characterization of Qi-Li-Qiang-Xin capsule-related xenobiotics in rats by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1090: 56-64. doi: 10.1016/j.jchromb.2018.05.014
[20] Tang XY, Dai ZQ, Zeng JX, et al. Pharmacokinetics, hepatic disposition, and heart tissue distribution of 14 compounds in rat after oral administration of Qi-Li-Qiang-Xin capsule via ultra-high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry[J]. J Sep Sci, 2022, 45(13): 2177-2189. doi: 10.1002/jssc.202101008
[21] He LL, Liu YH, Yang KF, et al. The discovery of Q-markers of Qiliqiangxin Capsule, a traditional Chinese medicine prescription in the treatment of chronic heart failure, based on a novel strategy of multi-dimensional"radar chart"mode evaluation[J]. Phytomedicine, 2021, 82: 153443. doi: 10.1016/j.phymed.2020.153443
[22] Zhang FG, Zhang Y, Li XF, et al. Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association[J]. Phytomedicine, 2018, 44: 220-230. doi: 10.1016/j.phymed.2018.03.003
[23] Hood WB Jr, Dans AL, Guyatt GH, et al. Digitalis for treatment of heart failure in patients in sinus rhythm[J]. Cochrane Database Syst Rev, 2014, 2014(4): CD002901.
[24] 官佳佳, 陈飞, 吴伽勒, 等. 芪苈强心胶囊改善糖尿病心力衰竭大鼠心功能及血管内皮功能实验研究[J]. 浙江中西医结合杂志, 2014, 24(8): 669-672. doi: 10.3969/j.issn.1005-4561.2014.08.004
[25] Liang T, Zhang YH, Yin SJ, et al. Cardio-protecteffect of qiliqiangxin capsule on left ventricular remodeling, dysfunction and apoptosis in heart failure rats after chronic myocardial infarction[J]. Am J Transl Res, 2016, 8(5): 2047-2058.
[26] Cui XN, Zhang J, Li YB, et al. Effects of Qili Qiangxin capsule on AQP2, V2R, and AT1R in rats with chronic heart failure[J]. Evid Based Complement Alternat Med, 2015, 2015: 639450.
[27] 马柳一, 尹玉洁, 张军芳, 等. 芪苈强心胶囊对慢性心衰大鼠下丘脑室旁核RAS系统及交感神经系统的影响[J]. 中国药理学通报, 2016, 32(4): 575-580. doi: 10.3969/j.issn.1001-1978.2016.04.026
[28] 秘红英, 郎艳松, 唐思文, 等. 经侧脑室注射芪苈强心胶囊对慢性心衰大鼠的影响[J]. 中药药理与临床, 2014, 30(5): 128-131.
[29] 白玲, 王军, 刘平, 等. 芪苈强心胶囊与美托洛尔对心力衰竭大鼠心功能及BNP影响的对比研究[J]. 中国循证心血管医学杂志, 2014, 6(4): 408-410.
[30] 秘红英. 慢性充血性心力衰竭大鼠下丘脑室旁核CRH神经元激活相关机制及芪苈强心胶囊干预研究[D]. 石家庄: 河北医科大学, 2015.
[31] Han AB, Lu YD, Zheng Q, et al. Qiliqiangxin attenuates cardiac remodeling via inhibition of TGF-β1/Smad3 and NF-κB signaling pathways in a rat model of myocardial infarction[J]. Cell Physiol Biochem, 2018, 45(5): 1797-1806.
[32] Xiao H, Song Y, Li Y, et al. Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction[J]. Cell Immunol, 2009, 260(1): 51-55.
[33] Liao YH, Yuan J, Jin XJ, et al. Qiliqiangxin alleviates imbalance of inflammatory cytokines in patients with dilated cardiomyopathy: a randomized controlled trial[J]. Curr Med Sci, 2024, Aug 28. doi: 10.1007/s11596-024-2916-9.
[34] 黄政, 方存明, 马小林, 等. 芪苈强心胶囊通过TLR4/NF-κB通路减轻心力衰竭大鼠心肌炎性反应的研究[J]. 重庆医学, 2020, 49(2): 183-187.
[35] 郝佳梦. 脉络学说指导芪苈强心胶囊治疗射血分数保留型心衰作用及机制研究[D]. 石家庄: 河北医科大学, 2022.
[36] Hao JM, Sun P, Zeng Y, et al. Qiliqiangxin capsule improves cardiac remodeling in rats with DOCA-salt-induced diastolic dysfunction[J]. Eur Rev Med Pharmacol Sci, 2023, 27(15): 7264-7275.
[37] Lu YD, Xiang M, Xin LY, et al. Qiliqiangxin modulates the gut microbiota and NLRP3 inflammasome to protect against ventricular remodeling in heart failure[J]. Front Pharmacol, 2022, 13: 905424.
[38] Zhao QF, Li HR, Chang LP, et al. Qiliqiangxin attenuates oxidative stress-induced mitochondrion-dependent apoptosis in cardiomyocytes via PI3K/AKT/GSK3β signaling pathway[J]. Biol Pharm Bull, 2019, 42(8): 1310-1321.
[39] Zhou JM, Jiang K, Ding XF, et al. Qiliqiangxin inhibits angiotensin Ⅱ-induced transdifferentiation of rat cardiac fibroblasts through suppressing interleukin-6[J]. J Cell Mol Med, 2015, 19(5): 1114-1121.
[40] 孙许涛, 钟晴, 张蓉, 等. 芪苈强心胶囊抑制阿霉素诱导的心肌成纤维细胞活化的作用机制研究[J]. 中医药学报, 2023, 51(12): 22-28.
[41] 纪晓迪, 吴爱明, 吕梦, 等. 基于miRNA-133a/TGF-β1/Smads信号通路探讨芪苈强心胶囊对心肌梗死大鼠心肌纤维化的作用机制[J]. 海南医学院学报, 2022, 28(21): 1608-1613.
[42] Sun XT, Chen GZ, Xie Y, et al. Qiliqiangxin improves cardiac function and attenuates cardiac remodelling in doxorubicin-induced heart failure rats[J]. Pharm Biol, 2020, 58(1): 417-426.
[43] Lin SH, Wu XT, Tao LC, et al. The metabolic effects of traditional Chinese medication qiliqiangxin on H9C2 cardiomyocytes[J]. Cell Physiol Biochem, 2015, 37(6): 2246-2256.
[44] Gao RR, Wu XD, Jiang HM, et al. Traditional Chinese medicine Qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy via upregulating PPARγ and PGC-1α[J]. Ann Transl Med, 2018, 6(8): 153.
[45] Wang YY, Fu MQ, Wang JF, et al. Qiliqiangxin improves cardiac function through regulating energy metabolism via HIF-1 α-dependent and independent mechanisms in heart failure rats after acute myocardial infarction[J]. Biomed Res Int, 2020: 1276195.
[46] Cheng WK, Wang L, Yang T, et al. Qiliqiangxin capsules optimize cardiac metabolism flexibility in rats with heart failure after myocardial infarction[J]. Front Physiol, 2020, 11: 805.
[47] Zhang JF, Wei C, Wang HT, et al. Protective effect of qiliqiangxin capsule on energy metabolism and myocardial mitochondria in pressure overload heart failure rats[J]. Evid Based Complement Alternat Med, 2013, 2013: 378298.
[48] Tao LC, Shen ST, Fu SY, et al. Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice[J]. Sci Rep, 2015, 5: 8374.
[49] 张军芳, 唐思文, 王宏涛, 等. 芪苈强心胶囊对压力超负荷心力衰竭大鼠内皮损伤及能量代谢的影响[J]. 中医杂志, 2013, 54(14): 1221-1224, 1229.
[50] Li FH, Wang JF, Song Y, et al. Qiliqiangxin alleviates Ang Ⅱ-induced CMECs apoptosis by downregulating autophagy via the ErbB2-AKT-FoxO3a axis[J]. Life Sci, 2021, 273: 119239. http://www.sciencedirect.com/science/article/pii/S0024320521002241
[51] Wang JF, Zhou JM, Wang YY, et al. Qiliqiangxin protects against anoxic injury in cardiac microvascular endothelial cells via NRG-1/ErbB-PI3K/Akt/mTOR pathway[J]. J Cell Mol Med, 2017, 21(9): 1905-1914.
[52] Wang YY, Zhang JJ, Fu MQ, et al. Qiliqiangxin prescription promotes angiogenesis of hypoxic primary rat cardiac microvascular endothelial cellsviaregulating miR-21 signaling[J]. Curr Pharm Des, 2021, 27(26): 2966-2974.
[53] Wang JF, Zhou JM, Ding XF, et al. Qiliqiangxin improves cardiac function and attenuates cardiac remodeling in rats with experimental myocardial infarction[J]. Int J Clin Exp Pathol, 2015, 8(6): 6596-6606.
[54] Zou YZ, Lin L, Ye Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice[J]. J Cardiovasc Pharmacol, 2012, 59(3): 268-280.
[55] Zhang JL, Huang MY, Shen ST, et al. Qiliqiangxin attenuates isoproterenol-induced cardiac remodeling in mice[J]. Am J Transl Res, 2017, 9(12): 5585-5593.
[56] Luo XX, Zhou JY, Wang ZX, et al. An inhibitor role of Nrf2 in the regulation of myocardial senescence and dysfunction after myocardial infarction[J]. Life Sci, 2020, 259: 118199.
[57] Ji XD, Yang D, Cui XY, et al. Mechanism of Qili Qiangxin capsule for heart failure based on miR133a-endoplasmic reticulum stress[J]. Chin J Integr Med, 2024, 30(5): 398-407.
[58] Zhou JY, Wang ZX, He Y, et al. Qiliqiangxin reduced cardiomyocytes apotosis and improved heart function in infarcted heart through Pink1/Parkin-mediated mitochondrial autophagy[J]. BMC Complement Med Ther, 2020, 20(1): 203.
[59] Fan CL, Cai WJ, Ye MN, et al. Qili Qiangxin, a compound herbal medicine formula, alleviates hypoxia-reoxygenation-induced apoptotic and autophagic cell death via suppression of ROS/AMPK/mTOR pathway in vitro[J]. J Integr Med, 2022, 20(4): 365-375.
[60] Qin YT, Lv C, Zhang XX, et al. Protective effect of qiliqiangxin against doxorubicin-induced cardiomyopathy by suppressing excessive autophagy and apoptosis[J]. Cardiovasc Ther, 2022: 9926635.
[61] Fan CL, Tang XY, Ye MN, et al. Qi-Li-Qiang-Xin alleviates isoproterenol-induced myocardial injury by inhibiting excessive autophagy via activating AKT/mTOR pathway[J]. Front Pharmacol, 2019, 10: 1329.
[62] Zhou Y, Fang H, Lin S, et al. Qiliqiangxin protects against cardiac ischemia-reperfusion injury via activation of the mTOR pathway[J]. Cell Physiol Biochem, 2015, 37(2): 454-464.
[63] Cheang I, Yao WM, Zhou YL, et al. The traditional Chinese medicine qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial[J]. Nat Med, 2024, 30: 2295-2302.
[64] Li XL, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure[J]. J Am Coll Cardiol, 2013, 62(12): 1065-1072.
[65] 毛天诗, 李宇轩, 庞彦廷, 等. 芪苈强心治疗慢性心力衰竭的meta分析[J]. 临床心血管病杂志, 2024, 40(12): 998-1005. doi: 10.13201/j.issn.1001-1439.2024.12.010
[66] 李彦霞, 贾振华, 张鑫月. 芪苈强心胶囊对慢性舒张性心力衰竭患者心脏舒张功能的影响[J]. 疑难病杂志, 2013, 12(4): 261-263.
[67] 巩贵宏, 张海波, 杨建涛, 等. 芪苈强心胶囊联合缬沙坦治疗舒张性心力衰竭的疗效观察[J]. 中西医结合心血管病电子杂志, 2015, 3(10): 128-129.
[68] 李三军, 余松平, 胡林, 等. 芪苈强心胶囊联合西药治疗舒张性心力衰竭临床研究[J]. 实用中医药杂志, 2023, 39(12): 2416-2418.
[69] 冯英, 蒋玙姝, 何倩雯, 等. 芪苈强心胶囊治疗舒张性心力衰竭的疗效及安全性的Meta分析[J]. 武汉大学学报(医学版), 2015, 36(6): 992-999.
-
图(2)
表(3)
计量
- 文章访问数: 1337
- PDF下载数: 297
- 施引文献: 0